Pharyngeal Liposarcoma: The importance of MDM2 testing for early diagnosis

Technical Summary: Pharyngeal Liposarcoma and the Role of MDM2 Testing

Problem Statement
Adipocytic tumors of the upper aerodigestive tract (pharynx, larynx, esophagus, oral cavity) present a significant diagnostic challenge. While liposarcomas (LPS) are generally recognized as locally aggressive malignancies in the extremities and retroperitoneum, those occurring in the head and neck are rare, accounting for only 0.12% of all liposarcomas. These lesions frequently mimic benign entities, such as lipomas, fibrolipomas, or reactive polypoid lesions (historically termed "giant fibrovascular polyps"). The histological features of well-differentiated liposarcoma (WDLPS) in this region are often "bland," lacking the overt cellular atypia typically required for a morphological diagnosis of malignancy. Consequently, clinical, radiological, and light microscopic evaluations alone are often non-specific, leading to a high rate of misclassification as benign. This misdiagnosis poses a risk of inadequate surgical management and potential local recurrence.

Methodology
This study employed a retrospective case series design utilizing the Pathology Queensland laboratory information systems. The search spanned from 1999 to 2023, employing keywords related to adipocytic tumors and upper aerodigestive tract sites (e.g., 'lipoma', 'liposarcoma', 'pharynx', 'larynx').

• Inclusion Criteria: Adipocytic tumors or giant fibrovascular polyps with an adipocytic component located in the pharynx, larynx, or esophagus.
• Data Collection: Clinical data (age, sex, tumor size, initial diagnosis, surgical management, follow-up) and histopathological slides were retrieved and re-evaluated by a histopathologist.
• Molecular Analysis: All cases underwent Fluorescence In Situ Hybridization (FISH) testing for MDM2 gene amplification, the gold standard for confirming WDLPS/atypical lipomatous tumors (ALT).
• Ethical Considerations: The study received institutional review board approval with a waiver of consent.

Key Results
Six cases met the inclusion criteria: five confirmed liposarcomas and one chondroid lipoma.

• Diagnostic Discrepancy: Four of the five liposarcoma cases were initially classified as benign (lipoma, spindle cell lipoma, or reactive lymphoid hyperplasia) or non-diagnostic upon original presentation. Only one case was provisionally suspected as liposarcoma pending molecular confirmation.
• Histological Heterogeneity: The liposarcomas exhibited significant morphological variability. Key features included:
  • Prominent non-lipogenic components (fibrous stroma, fibro-inflammatory zones) comprising up to 80% of the tumor in some cases.
  • Scarcity or absence of lipoblasts (absent in 3 cases, rare in 2).
  • Inconsistent distribution of hyperchromatic stromal cells; one case showed no atypical cells, while another showed frequent atypia.
  • No high-grade dedifferentiation, necrosis, or significant mitotic activity was observed.
• Molecular Findings: All five liposarcoma cases demonstrated MDM2 amplification via FISH. The single chondroid lipoma case was negative for MDM2 amplification.
• Clinical Outcomes: Two of the five liposarcoma cases experienced local recurrence. One patient died during follow-up, though the cause of death was attributed to comorbidities rather than the tumor.

Key Contributions
The paper provides empirical evidence supporting the following conclusions:

1. Prevalence of Malignancy: Adipocytic tumors in the upper aerodigestive tract are disproportionately represented by liposarcomas rather than benign lipomas. The authors note that in their 24-year review of local data, no pharyngeal lipoma was confirmed without subsequent reclassification to liposarcoma upon molecular review.
2. Limitations of Morphology: Histological features in pharyngeal LPS are often deceptively bland. The absence of overt atypia or lipoblasts does not rule out malignancy. Inflammatory components can further obscure diagnostic features, leading to misdiagnosis as reactive processes.
3. Necessity of Molecular Confirmation: MDM2 amplification testing is critical for resolving ambiguous adipocytic lesions in this anatomical region. The study demonstrates that reliance on histology alone leads to a high rate of under-diagnosis.
4. Re-evaluation of "Giant Fibrovascular Polyps": The findings suggest that many lesions historically diagnosed as benign giant fibrovascular polyps (GFP) may actually represent well-differentiated liposarcomas, particularly when they harbor subtle stromal atypia or non-lipogenic spindle cell components.

Significance
The authors assert that the diagnostic workflow for adipocytic tumors in the upper aerodigestive tract must be fundamentally altered. Given the high risk of misclassification and the potential for local recurrence, routine MDM2 amplification testing (via FISH or droplet digital PCR) is indispensable. This molecular confirmation is required to distinguish liposarcoma from benign mimics, ensuring appropriate surgical management and preventing the morbidity associated with local recurrence. The study concludes that objective molecular tools are the only reliable method to secure a definitive diagnosis in these morphologically ambiguous cases.